Growth of the majority of breast cancers is stimulated by oestrogen and this oestrogen receptor (ER) signalling can be successfully blocked by anti-hormonal treatments, including aromatase inhibitors or the oestrogen receptor antagonists, tamoxifen or fulvestrant. This evidence concerns the gene CYP19A1 and breast cancer.